在焦点中探索辅助赛诺巴酸的有效性:基于时间的分析
Roberta Roberti1, Gianfranco Di Gennaro1, Vittoria Cianci2
1Department of Health Sciences, University of Catanzaro "Magna Græcia", Viale Europa, 88100, Catanzaro, Italy.
CNS drugs
|February 27, 2025
概括
塞诺巴 (CNB) 补充疗法显示出潜在的焦点发作发作,趋势表明与GABAergics结合并没有通道阻断剂 (SCBs) 时,结果更好. 为了获得最佳的ASM组合,还需要进一步的研究.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 越来越多的证据支持塞诺巴马特 (CNB) 对的有效性.
- 本研究评估了CNB的临床反应,使用时间到事件分析.
- 探讨了同时服用抗发作药物 (ASM) 对CNB疗效的影响.
研究的目的:
- 为了评估在焦点发作发作的成年人中添加酸 (CNB) 的实际有效性.
- 研究同时服用抗发作药物 (ASM) 对CNB治疗结果的影响.
- 分析时间到事件数据以控制发作和与CNB相关的不良事件.
主要方法:
- 在意大利扩展访问计划中对92名成年人进行的一项回顾性多中心研究的子组分析.
- 主要终点:达到基线发作数量的时间.
- 二级终点:发作反应,发作自由,停药率和不良事件 (AE).
主要成果:
- 在12个月后,发作反应率为42.0%,发作自由率为13.6%,断率为23.9%.
- 趋势表明,与其他ASM组合相比,单独使用GABAergics可以改善控制和减少AE,尽管在统计上并不显著.
- 51.1%的参与者经历了副作用,主要是昏昏欲睡,头和平衡障碍.
结论:
- 时间到事件分析提供了对附加CNB有效性的真实洞察.
- 对CNB与GABAergics结合并没有SCBs观察到的有利趋势需要进一步调查.
- 确定最佳的ASM与CNB组合对于最大限度地控制和耐受性至关重要.
更多相关视频
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
8.9K
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
11.9K
相关概念视频
01:14Antiepileptic Drugs: Glutamate Antagonists
267
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
267
01:20Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209
01:17Antiepileptic Drugs: Calcium Channel Blockers
290
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
290
01:08Antiepileptic Drugs: Sodium Channel Blockers
340
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
340
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
306
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
306